The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study

NCT06610045 | Completed

• 1 other identifier: PROxy202301
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL. Additionally, this study will assess the correlation between QoL, obtained from commonly used and validated questionnaires, and the perceptions of both patients and caregivers respectively., obtain from a 10-point scale and a comment box.

Conditions

Multiple Myeloma; Caregiver Subjective Burden; Quality of Life (QOL)

Keywords

quality of life; real-world; observational; myeloma; caregiver

Outcome Measures

Primary Outcomes (1)

• To estimate quality of life of patients with myeloma and caregivers of patients with myeloma

  From enrollment until sample size is reached

Secondary Outcomes (1)

• To assess the correlation between QoL scores and perception of patients and caregivers respectively

  From recruitment until sample size is reached

Study Arms (2)

Patients with multiple myeloma

Patients with multiple myeloma member of Myeloma Canada database

Other: No intervention

Caregivers of patients with myeloma

Caregiver of a multiple myeloma patient member of Myeloma Canada database

Other: No intervention

Interventions

No intervention OTHER

No specific intervention is assess in this study.

Caregivers of patients with myeloma; Patients with multiple myeloma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with myeloma and caregivers of patients with myeloma who are part of Myeloma Canada database

You may qualify if:

• years of age or older;
• Part of the Myeloma Canada database;
• Identified as a patient with MM or
• Identified as a current caregiver of a patient with MM at the time of participation.
• Ability to read and understand English or French;
• Signature of informed consent form (ICF).

Sponsors & Collaborators

• PeriPharm: lead

Study Sites (1)

PROxy Network, an initiative of PeriPharm inc.

Montreal, Quebec, H2Y 2H4, Canada

Location

MeSH Terms

Conditions

Multiple Myeloma; Neoplasms, Plasma Cell

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 12, 2024
• First Posted: September 24, 2024
• Study Start: October 15, 2024
• Primary Completion: February 24, 2025
• Study Completion: March 12, 2025
• Last Updated: March 13, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)